Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Trial Results
Biotech
Merck halts ph. 2 Alzheimer’s trial after underwhelming efficacy
Merck stopped the study after the small molecule MK-1167 “did not meet the necessary efficacy criteria to warrant further investigation."
Darren Incorvaia
Jul 1, 2026 2:35pm
Otsuka posts phase 3b ADHD trial win ahead of looming FDA ruling
Jun 25, 2026 9:13am
Definium’s LSD depression drug produces ‘best ever’ ph. 3 data
Jun 22, 2026 7:00am
Autobahn races toward ph. 3 after midstage bipolar depression win
Jun 4, 2026 11:31am
At ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms
Jun 1, 2026 3:55pm
ASCO: Lilly's faith in Kelonia rewarded with ‘nutty’ CAR-T data
May 31, 2026 8:00am
